QMS Medical Allied Services has set an ambitious revenue target of ₹500 crore for fiscal year 2029, aiming to triple its top line within three years.
The company, which recently migrated to the NSE Mainboard, reported ₹172.9 crore in revenue and ₹25.9 crore in EBITDA for FY26.
Management projects that services revenue will double in FY27 and surpass product sales by FY28, marking a significant shift in the firm's business mix.
The growth strategy hinges on expanding its healthcare services and patient engagement business, which management views as the primary engine for future expansion.
This pivot suggests a deliberate move away from reliance on traditional medical device sales toward higher-margin, recurring service contracts.
The NSE Mainboard listing is expected to provide the capital market visibility and liquidity necessary to support this accelerated growth trajectory.